Immune Aging in Rheumatoid Arthritis
Arthritis & Rheumatology · 2025-07 · 77 (7) · 792-804
DOI: 10.1002/art.43105 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arthritis & Rheumatology, online erschienen am 11.02.2025. Verfasst von Cornelia M Weyand und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Alix School of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, and Stanford University School of Medicine, S…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Aging, CD4-Positive T-Lymphocytes, Immunosenescence. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, CLC NIH HHS.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a life‐long autoimmune disease caused by the confluence of genetic and environmental variables that lead to loss of self‐tolerance and persistent joint inflammation. RA occurs at the highest incidence in individuals >65 years old, implicating the aging process in disease susceptibility. Transformative approaches in molecular immunology and in functional genomics have paved the way for pathway paradigms underlying the replacement of immune homeostasis with autodestructive immunity in affected patients, including the process of immune aging. Patients with RA have a signature of premature immune aging, best understood for CD4 + T cells, which function as pathogenic effectors in this HLA class II–associated disease. Premature immune aging is present in healthy HLA–DRB1*04 + individuals, placing accelerated immune aging before joint inflammation. Aging‐related molecular abnormalities directly implicated in turning RA CD4 + T cells into proinflammatory effector cells are linked to malfunction of subcellular organelles, such as mitochondria, lysosomes, lipid droplets, and the endoplasmic reticulum. Resulting changes in T cell behavior include cellular hypermobility, tissue invasiveness, unopposed mammalian target of rapamycin complex (mTORC)1 activation, excessive release of tumor necrosis factor, lysosomal failure, clonal expansion, and immunogenic cell death. Aged and metabolically reprogrammed T cells in patients with RA are accompanied by age‐associated B cells, which specialize in autoantibody production. Clonal hematopoiesis drives myeloid cell aging by producing aged monocytes and hypermetabolic macrophages, which sustain the process of inflammaging. Here, we synthesize insights into the relationship of RA risk and immune aging and discuss mechanisms through which immune aging can cause autoimmunity. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Mayo Clinic Alix School of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, and Stanford University School of Medicine, Stanford, California.
ORCID-Profile: Cornelia M Weyand
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- CLC NIH HHS
- NIAMS NIH HHS
- NIA NIH HHS
- Clinical Center
Zitieren
APA
Weyand, C. M., & Goronzy, J. J. (2025). Immune Aging in Rheumatoid Arthritis. Arthritis & Rheumatology, 77(7), 792-804. https://doi.org/10.1002/art.43105
Vancouver
Weyand CM, Goronzy JJ. Immune Aging in Rheumatoid Arthritis. Arthritis & Rheumatology. 2025;77(7):792-804. doi:10.1002/art.43105
BibTeX
@article{Weyand2025,
author = {Weyand, Cornelia M and Goronzy, Jörg J},
title = {Immune Aging in Rheumatoid Arthritis},
journal = {Arthritis & Rheumatology},
year = {2025},
volume = {77},
number = {7},
pages = {792--804},
doi = {10.1002/art.43105}
}
EUVIMED